{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-026568","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.922016+00:00","generated_at":"2026-06-12T12:42:54.133637+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ardelyx Q2 2023: IBSRELA rev $18.3M (+61% QoQ), net loss $17.1M, FY23 guidance $72-77M","bullets":["IBSRELA net sales $18.3M in Q2 2023, up 61% QoQ from $11.4M in Q1.","Total revenues $22.3M (incl $4.0M licensing); net loss $17.1M ($0.08/sh) narrowed from $26.9M loss in Q2 2022.","FY2023 IBSRELA net sales guided to $72-77M; management sees $500M+ peak sales potential.","XPHOZAH NDA under FDA review (PDUFA Oct 17, 2023); launch prep underway for Q4 2023 pending approval.","Cash $127.6M at June 30, 2023; raised $11.6M via ATM in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-026568","json":"https://secwatch.observer/filing/0001628280-23-026568.json","markdown":"https://secwatch.observer/filing/0001628280-23-026568.md","text":"https://secwatch.observer/filing/0001628280-23-026568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/0001628280-23-026568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/ardx-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:42:54.133637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"932990864940734271bbc8ffd0c0bbdae9fd66fe","claim":"ARDELYX, INC. reported second quarter ended June 30, 2023 results: revenue $22.3 million. Guidance raised.","evidence_excerpt":"for IBSRELA were $18.3 million during the quarter ended June 30, 2023, compared to $1.6 million for the quarter ended June 30, 2022. Total revenues for the second quarter were $22.3 million, which included $4.0 million of product supply and licensing related revenue compared to $1.0 million in product supply and licensing related revenue in the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/0001628280-23-026568-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$22.3 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}